This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(Currently Amended)** ~~Pharmaceutical~~ A pharmaceutical composition comprising, ~~as active principles,~~

(i) at least one α-glucosidase inhibitor that is miglitol, voglibose or emiglitate

and

(ii) at least one acid that is ~~compound of the formula (I), in combination with one or more pharmaceutically acceptable excipients, the compound of the formula (I) being defined as follows:~~



(I)

~~in which the groups A and B are chosen, independently of each other, from:~~

~~- a mono-, bi- or tricyclic aryl group containing from 6 to 14 carbon atoms;~~

~~- a heteroaromatic group chosen from pyridyl, pyrimidyl, pyrrolyl, furyl and thienyl groups;~~

~~- an alkyl group containing from 1 to 14 carbon atoms;~~

~~- a cycloalkyl group containing from 5 to 8 carbon atoms;~~

~~- a saturated heterocyclic group chosen from tetrahydrofuryl, tetrahydropyranyl, piperidyl and pyrrolidinyl groups;~~

~~the groups A and B possibly bearing 1 to 3 substituents chosen from a C_1-C_6-alkyl group, a C_1-C_6-alkoxy group, a C_6-C_{14}-aryl group, a heteroaryl group chosen from pyridyl, pyrimidyl, pyrrolyl, furyl and thienyl, a (C_6-C_{14})aryl(C_1-C_6)alkyl group, a (C_6-C_{14})aryl(C_1-C_6)alkyl(C_6-C_{14})aryl group, a halogen or a trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, nitro, amino, carboxyl, (C_1-C_6)alkoxycarbonyl, carbamoyl, (C_1-C_6)alkylsulfonyl, sulfoamino,~~

~~(C_1-C_6)alkylsulfonylamino, sulfamoyl or (C_1-C_6)alkylcarbonylamino group;~~

~~or two of the substituents forming a methylenedioxy group~~,

- 2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid,
- 2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid,
- 2-cyclohexylmethyl-4-(4-methoxyphenyl)-4-oxobutanoic acid,
- 2-benzyl-4-phenyl-4-oxobutanoic acid,
- 2-(β-naphthylmethyl)-4-phenyl-4-oxobutanoic acid,
- 2-benzyl-4-(β-naphthyl)-4-oxobutanoic acid,
- 2-[(4-chlorophenyl)methyl]-4-(4-methoxyphenyl)-4-oxobutanoic acid,
- 2-benzyl-4-(4-methylphenyl)-4-oxobutanoic acid,
- 4-(4-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-4-oxobutanoic acid,
- 2-benzyl-4-(3,4-methylenedioxyphenyl)-4-oxobutanoic acid,
- 2-benzyl-4-cyclohexyl-4-oxobutanoic acid,
- 4-phenyl-2-[(tetrahydrofur-2-yl)methyl]-4-oxobutanoic acid,
- (-)-2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid,
- (+)-2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid,
- (-)-2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid,
- (+)-2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid or

a solvate, enantiomer or salt thereof ~~or a salt of this acid~~,

in combination with one or more pharmaceutically acceptable excipients.

2. **(Currently Amended)** A pharmaceutical composition ~~Composition~~ according to Claim 1 for treating diabetes.

3. **(Currently Amended)** A pharmaceutical composition ~~Composition~~ according to claim 1 for treating non-insulin-dependent diabetes.

4. **(Currently Amended)** A pharmaceutical composition ~~Composition~~ according to Claim 1 for treating at least one of the pathologies associated with insulin resistance

syndrome, ~~more particularly chosen from~~ dyslipidaemia, obesity, arterial hypertension, ~~and~~ microvascular complications, ~~and~~ macrovascular complications, ~~for instance~~ atherosclerosis, retinopathies, nephropathies ~~and~~ or neuropathies.

5. **(Currently Amended)** ~~Pharmaceutical~~ A pharmaceutical composition according to claim 1, ~~characterised in that~~ wherein the weight ratio of (i) ~~α-glycosidase inhibitor~~ miglitol, voglibose or emiglitate to (ii) the acid ~~compound of the formula (I)~~ ranges from 10^{-3} to 40~~, preferably from 10^{-3} to 10 and better still from 10^{-3} to 5~~.

6. **(Currently amended)** ~~Pharmaceutical~~ A pharmaceutical composition according to claim 1, ~~characterised in that~~ wherein the α-glucosidase inhibitor is ~~chosen from acarbose, miglitol, voglibose and~~ emiglitate.

7. **(Currently Amended)** A pharmaceutical composition ~~Composition~~ according to claim 1, ~~characterised in that~~ wherein the (ii) acid ~~compound of the formula (I)~~ is ~~chosen from~~:

~~2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid~~

- 2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid
- or a salt, solvate or enantiomer thereof

~~2-cyclohexylmethyl-4-(4-methoxyphenyl)-4-oxobutanoic acid~~

~~2-benzyl-4-phenyl-4-oxobutanoic acid~~

~~2-(β-naphthylmethyl)-4-phenyl-4-oxobutanoic acid~~

~~2-benzyl-4-(β-naphthyl)-4-oxobutanoic acid~~

~~2-[(4-chlorophenyl)methyl]-4-(4-methoxyphenyl)-4-oxobutanoic acid~~

~~2-benzyl-4-(4-methylphenyl)-4-oxobutanoic acid~~

~~4-(4-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-4-oxobutanoic acid~~

~~2-benzyl-4-(3,4-methylenedioxyphenyl)-4-oxobutanoic acid~~

~~2-benzyl-4-cyclohexyl-4-oxobutanoic acid~~

~~4-phenyl-2-[(tetrahydrofur-2-yl)methyl]-4-oxobutanoic acid,~~

~~the solvates, enantiomers and salts of these acids~~.

8. (Currently amended) A pharmaceutical composition ~~Composition~~ according to claim ~~1~~ 7, ~~characterised in that~~ wherein the ~~compound of the formula (I)~~ (ii) acid is ~~chosen from~~:

~~(-) 2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid~~

~~(+) 2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid~~

~~(-) 2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid~~

(+)-2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid.

9. **(Currently Amended)** A pharmaceutical composition ~~Composition~~ according to claim 1, which is suitable for oral administration.

10.**(Withdrawn-Currently Amended)** A method for the preparation of a medicinal combination for treating diabetes comprising combining ~~Use of an~~ (i) an α-glucosidase inhibitor that is miglitol, voglibose or emiglitate ~~in combination~~ with ~~a compound of the formula (I)~~ (ii) an acid as defined in Claim 1 ~~for the preparation of a medicinal combination for treating diabetes~~.

11.**(Withdrawn-Currently Amended)** ~~Use~~ A method according to Claim 10 for the preparation of a medicinal combination for treating non-insulin-dependent diabetes.

12.**(Withdrawn-Currently Amended)** ~~Use of an α-glucosidase inhibitor in combination with a compound of the formula (I) as defined in Claim 1 for~~ A method for the preparation of a medicinal combination for treating at least one of the pathologies associated with insulin resistance syndrome, ~~more particularly chosen from~~ dyslipidaemia, obesity, arterial hypertension, ~~and~~ microvascular complications, ~~and~~ macrovascular complications, ~~for instance~~ atherosclerosis, retinopathies, nephropathies ~~and~~ or neuropathies comprising (i) an α-glucosidase inhibitor that is miglitol, voglibose or emiglitate combined with (ii) an acid as defined in Claim 1

13.**(Withdrawn-Currently Amended)** ~~Use~~ A method according to claim 10,

~~characterised in that~~ wherein the α-glucosidase inhibitor is ~~chosen from~~ ~~acarbose~~, miglitol, ~~voglibose and emiglitate~~.

14.**(Withdrawn-Currently Amended)** ~~Use~~ A method according to claim 10, ~~characterised in that~~ wherein the acid (ii) is ~~compound of the formula (I) is chosen from~~:

- ~~2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid~~
- 2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid
- or a salt, solvate or enantiomer thereof
- ~~2-cyclohexylmethyl-4-(4-methoxyphenyl)-4-oxobutanoic acid~~
- ~~2-benzyl-4-phenyl-4-oxobutanoic acid~~
- ~~2-(β-naphthylmethyl)-4-phenyl-4-oxobutanoic acid~~
- ~~2-benzyl-4-(β-naphthyl)-4-oxobutanoic acid~~
- ~~2-[(4-chlorophenyl)methyl]-4-(4-methoxyphenyl)-4-oxobutanoic acid~~
- ~~2-benzyl-4-(4-methylphenyl)-4-oxobutanoic acid~~
- ~~4-(4-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-4-oxobutanoic acid~~
- ~~2-benzyl-4-(3,4-methylenedioxyphenyl)-4-oxobutanoic acid~~
- ~~2-benzyl-4-cyclohexyl-4-oxobutanoic acid~~
- ~~4-phenyl-2-[(tetrahydrofur-2-yl)methyl]-4-oxobutanoic acid,~~

~~the solvates, enantiomers and salts of these acids~~.

15.**(Withdrawn-Currently Amended)** ~~Use~~ A method according to claim 10, ~~characterised in that~~ wherein the medicinal combination is in the form of a unit dose comprising (i) an α-glucosidase inhibitor that is miglitol, voglibose or emiglitate and (ii) a salt ~~compound of the formula (I)~~.

16.**(Withdrawn-Currently Amended)** ~~Use~~ A pharmaceutical compound according to claim 1, ~~characterised in that~~ wherein the unit dose comprises from 0.1 mg to 400 mg of (i) an α-glucosidase inhibitor that is miglitol, voglibose or emiglitate and from 12.5 to 400 mg of said (ii) ~~compound of the formula (I)~~.

17. **(New)** A pharmaceutical composition according to claim 5,wherein the weight ratio of (i) to (ii) is from 10^{-3} to 10.

18. **(New)** A pharmaceutical composition according to claim 17,wherein the weight ratio of (i) to (ii) is from 10^{-3} to 5.